News
Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...
Tiziana Life Sciences has announced the commencement of dosing in the fourth clinical site of the company’s Phase II trial of ...
The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...
At ESCMID 2025, early data suggest that Assembly Biosciences’ ABI-5366 could redefine the treatment landscape for recurrent genital herpes (RGH).
Lokavant has launched the AI-powered clinical trial forecasting solution, Spectrum v15, to dispel uncertainty in the ...
BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...
Cellphire Therapeutics has stopped enrolling subjects in its CRYPTICS trial of CLPH-511 following feedback from an IDMC.
According to the WHO, meningitis is a significant global health threat even though treatments and vaccines against some forms ...
Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s ...
EAGLE-1 trial data shows gepotidacin’s potential in treating gonorrhoea, for which no new antibiotics have been approved ...
Contraception for women has seen little change over the past 50 years, with the most prevalent contraceptive pills containing ...
Daiichi and AstraZeneca's Enhertu with pertuzumab has shown PFS improvement in the Phase III DESTINY-Breast09 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results